Summary

U.S. Neurology Clinical Trials Market Summary

The U.S. neurology clinical trials market size was estimated at USD 2.53 billion in 2024 and is projected to reach USD 4.47 billion by 2033, growing at a CAGR of 6.59% from 2025 to 2033. The growth of the U.S. market for neurology clinical trials is driven by significant advancements in neuroscience, increasing healthcare spending, and an emphasis on targeted therapies for intricate neurological conditions.

Other factors driving the growth of the U.S. neurology clinical trials industry include increasing patient awareness, regulatory support for orphan drugs and breakthrough therapies, and rising investment in neurology research and development. The rising incidence of neurodegenerative diseases, supported by a well-established clinical research infrastructure, has established the U.S. as a key center for neurology trials. Furthermore, funding from both public and private sectors and strategic partnerships among pharmaceutical companies, contract research organizations (CROs), and academic institutions have played a crucial role in speeding up study timelines and enhancing trial efficiency, further supporting the market.

The increasing prevalence of Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and various rare neurological syndromes has created an increased need for novel treatment options, resulting in a rise in the number of clinical trial activities. These studies are conducted in early and late stages, with more advanced programs concentrating on disease-modifying therapies, neuroprotective agents, and gene-based interventions. In addition, pharmaceutical and biotechnology companies are expanding in-house CRO capabilities to maintain control over study protocols, enhance execution speed, and increase operational efficiency for clinical trials. Besides, a growing number of investigator sites specializing in neurology are further improving patient recruitment accuracy, optimizing trial quality, and shortening enrollment timelines. This blend of in-house capabilities and specialized site expertise boosts the scale and rate of neurological trial delivery across the country.

Moreover, market trends are shifting towards adopting decentralized and hybrid trial models, allowing for broader patient participation and faster data collection. Further, the growing incorporation of advanced neuroimaging techniques, biomarker-based diagnostics, and AI-driven patient selection tools is enhancing the precision of trials and the predictability of outcomes. Furthermore, numerous biopharmaceutical companies are expanding their neurology research portfolios and site networks to strengthen their geographic reach, accelerate regulatory approvals, and better address the unmet needs of patients in underserved areas, further supporting the U.S. neurology clinical trials market.

Thus, the neurology clinical trials market is crucial to the U.S. healthcare industry, as it tackles conditions that heavily influence healthcare costs, workforce productivity, and patients' overall quality of life. Besides, these trials are essential for converting scientific innovations into market-ready treatments while reducing disease burden. Such aforementioned factors are expected to drive the market over the estimated timeframe.

U.S. Neurology Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. neurology clinical trials market report based onphase, study design, indication, indication by study design, indication by phase, and value chain:
• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Phase IV
• Study Design Outlook (Revenue, USD Million, 2021 - 2033)
• Interventional
• Observational
• Expanded Access
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Alzheimer’s Disease
• Depression (MDD)
• Parkinson's Disease (PD)
• Epilepsy
• Stroke
• Traumatic Brain Injury (TBI)
• Amyotrophic Lateral Sclerosis (ALS)
• Huntington's Disease
• Muscle Regeneration
• Others
• Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
• Alzheimer’s Disease
o Interventional
o Observational
o Expanded Access
• Depression (MDD)
o Interventional
o Observational
o Expanded Access
• Parkinson's Disease (PD)
o Interventional
o Observational
o Expanded Access
• Epilepsy
o Interventional
o Observational
o Expanded Access
• Stroke
o Interventional
o Observational
o Expanded Access
• Traumatic Brain Injury (TBI)
o Interventional
o Observational
o Expanded Access
• Amyotrophic Lateral Sclerosis (ALS)
o Interventional
o Observational
o Expanded Access
• Huntington's Disease
o Interventional
o Observational
o Expanded Access
• Muscle Regeneration
o Interventional
o Observational
o Expanded Access
• Others
o Interventional
o Observational
o Expanded Access
• Indication by Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Alzheimer’s Disease
o Phase I
o Phase II
o Phase III
o Phase IV
• Depression (MDD)
o Phase I
o Phase II
o Phase III
o Phase IV
• Parkinson's Disease (PD)
o Phase I
o Phase II
o Phase III
o Phase IV
• Epilepsy
o Phase I
o Phase II
o Phase III
o Phase IV
• Stroke
o Phase I
o Phase II
o Phase III
o Phase IV
• Traumatic Brain Injury (TBI)
o Phase I
o Phase II
o Phase III
o Phase IV
• Amyotrophic Lateral Sclerosis (ALS)
o Phase I
o Phase II
o Phase III
o Phase IV
• Huntington's Disease
o Phase I
o Phase II
o Phase III
o Phase IV
• Muscle Regeneration
o Phase I
o Phase II
o Phase III
o Phase IV
• Others
o Phase I
o Phase II
o Phase III
o Phase IV
• Value Chain Outlook (Revenue, USD Million, 2021 - 2033)
• In-house
• CROs
• Investigator Sites/ Clinical Sites

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Study Design
1.2.2. Indication
1.2.3. Indication by Study Design
1.2.4. Indication by Phase
1.2.5. Value Chain
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.7.3. Bottom-Up Analysis
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Neurology Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of neurological diseases such as Alzheimer's disease, epilepsy, and stroke
3.2.1.2. Growing adoption of novel technologies in clinical research
3.2.1.3. Rising number of CROs providing U.S. Neurology Clinical research services
3.2.1.4. Increasing funding for neurological studies by public organizations
3.2.2. Market Restraint Analysis
3.2.2.1. Increased associated with U.S. Neurology Clinical studies
3.2.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials
3.2.3. Market Challenges
3.2.4. Market Opportunities
3.3. R&D Spending Analysis (2021-2024)
3.4. Technology Landscape
3.5. Pricing Model Analysis
3.6. Clinical Trial Volume Analysis, 2024
3.6.1. Total Number of U.S. Neurology Clinical Trials, by Phase, 2024
3.6.2. Total Number of U.S. Neurology Clinical Trials, by Study Design, 2024
3.6.3. Total Number of U.S. Neurology Clinical Trials, by Key Indication, 2024
3.7. Tariff Impact Analysis
3.8. Value Chain Analysis
3.8.1. Supply Trends
3.8.2. Demand Trends
3.9. Market Analysis Tools
3.9.1. Porter’s Five Forces Analysis
3.9.2. PESTEL by SWOT Analysis
Chapter 4. U.S. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. U.S. Neurology Clinical Trials Market, By Phase: Segment Dashboard
4.2. U.S. Neurology Clinical Trials Market, By Phase: Movement Analysis
4.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Phase, 2021 - 2033 (USD Million)
4.4. Phase I
4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Phase II
4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Phase III
4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Phase IV
4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. U.S. Neurology Clinical Trials Market, By Study Design: Segment Dashboard
5.2. U.S. Neurology Clinical Trials Market, By Study Design: Movement Analysis
5.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Study Design, 2021 - 2033 (USD Million)
5.4. Interventional
5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Observational
5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Expanded Access
5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. U.S. Neurology Clinical Trials Market, By Indication: Segment Dashboard
6.2. U.S. Neurology Clinical Trials Market, By Indication: Movement Analysis
6.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
6.4. Alzheimer’s Disease
6.4.1. Alzheimer’s Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Depression (MDD)
6.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Parkinson's Disease (PD)
6.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Epilepsy
6.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Stroke
6.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Traumatic Brain Injury (TBI)
6.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.10. Amyotrophic Lateral Sclerosis (ALS)
6.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.11. Huntington's Disease
6.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.12. Muscle Regeneration
6.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.13. Others
6.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Neurology Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis
7.1. U.S. Neurology Clinical Trials Market, Indication by Study Design: Segment Dashboard
7.2. U.S. Neurology Clinical Trials Market, Indication by Study Design: Movement Analysis
7.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
7.4. Alzheimer’s Disease
7.4.1. Alzheimer’s Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.2. Alzheimer’s Disease Interventional
7.4.2.1. Alzheimer’s Disease Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.3. Alzheimer’s Disease Observational
7.4.3.1. Alzheimer’s Disease Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.4. Alzheimer’s Disease Expanded Access
7.4.4.1. Alzheimer’s Disease Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Depression (MDD)
7.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.2. Depression (MDD) Interventional
7.5.2.1. Depression (MDD) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.3. Depression (MDD) Observational
7.5.3.1. Depression (MDD) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.4. Depression (MDD) Expanded Access
7.5.4.1. Depression (MDD) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Parkinson’s Disease (PD)
7.6.1. Parkinson’s Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.2. Parkinson’s Disease (PD) Interventional
7.6.2.1. Parkinson’s Disease (PD) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.3. Parkinson’s Disease (PD) Observational
7.6.3.1. Parkinson’s Disease (PD) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.4. Parkinson’s Disease (PD) Expanded Access
7.6.4.1. Parkinson’s Disease (PD) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Epilepsy
7.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.2. Epilepsy Interventional
7.7.2.1. Epilepsy Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.3. Epilepsy Observational
7.7.3.1. Epilepsy Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.4. Epilepsy Expanded Access
7.7.4.1. Epilepsy Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Stroke
7.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.2. Stroke Interventional
7.8.2.1. Stroke Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.3. Stroke Observational
7.8.3.1. Stroke Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.4. Stroke Expanded Access
7.8.4.1. Stroke Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.9. Traumatic Brain Injury (TBI)
7.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.9.2. Traumatic Brain Injury (TBI) Interventional
7.9.2.1. Traumatic Brain Injury (TBI) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.9.3. Traumatic Brain Injury (TBI) Observational
7.9.3.1. Traumatic Brain Injury (TBI) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.9.4. Traumatic Brain Injury (TBI) Expanded Access
7.9.4.1. Traumatic Brain Injury (TBI) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.10. Amyotrophic Lateral Sclerosis (ALS)
7.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.10.2. Amyotrophic Lateral Sclerosis (ALS) Interventional
7.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.10.3. Amyotrophic Lateral Sclerosis (ALS) Observational
7.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.10.4. Amyotrophic Lateral Sclerosis (ALS) Expanded Access
7.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.11. Huntington’s Disease
7.11.1. Huntington’s Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.11.2. Huntington’s Disease Interventional
7.11.2.1. Huntington’s Disease Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.11.3. Huntington’s Disease Observational
7.11.3.1. Huntington’s Disease Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.11.4. Huntington’s Disease Expanded Access
7.11.4.1. Huntington’s Disease Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.12. Muscle Regeneration
7.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.12.2. Muscle Regeneration Interventional
7.12.2.1. Muscle Regeneration Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.12.3. Muscle Regeneration Observational
7.12.3.1. Muscle Regeneration Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.12.4. Muscle Regeneration Expanded Access
7.12.4.1. Muscle Regeneration Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.13. Others
7.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.13.2. Others Interventional
7.13.2.1. Others Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.13.3. Others Observational
7.13.3.1. Others Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.13.4. Others Expanded Access
7.13.4.1. Others Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. U.S. Neurology Clinical Trials Market: Indication by Phase Estimates & Trend Analysis
8.1. U.S. Neurology Clinical Trials Market, Indication by Phase: Segment Dashboard
8.2. U.S. Neurology Clinical Trials Market, Indication by Phase: Movement Analysis
8.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Phase, 2021 - 2033 (USD Million)
8.4. Alzheimer’s Disease
8.4.1. Alzheimer’s Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.2. Alzheimer’s Disease Phase I
8.4.2.1. Alzheimer’s Disease Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.3. Alzheimer’s Disease Phase II
8.4.3.1. Alzheimer’s Disease Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.4. Alzheimer’s Disease Phase III
8.4.4.1. Alzheimer’s Disease Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.5. Alzheimer’s Disease Phase IV
8.4.5.1. Alzheimer’s Disease Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Depression (MDD)
8.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. Depression (MDD) Phase I
8.5.2.1. Depression (MDD) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. Depression (MDD) Phase II
8.5.3.1. Depression (MDD) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. Depression (MDD) Phase III
8.5.4.1. Depression (MDD) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Depression (MDD) Phase IV
8.5.5.1. Depression (MDD) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Parkinson's Disease (PD)
8.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. Parkinson's Disease (PD) Phase I
8.6.2.1. Parkinson's Disease (PD) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. Parkinson's Disease (PD) Phase II
8.6.3.1. Parkinson's Disease (PD) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.4. Parkinson's Disease (PD) Phase III
8.6.4.1. Parkinson's Disease (PD) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.5. Parkinson's Disease (PD) Phase IV
8.6.5.1. Parkinson's Disease (PD) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Epilepsy
8.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. Epilepsy Phase I
8.7.2.1. Epilepsy Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Epilepsy Phase II
8.7.3.1. Epilepsy Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.4. Epilepsy Phase III
8.7.4.1. Epilepsy Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.5. Epilepsy Phase IV
8.7.5.1. Epilepsy Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Stroke
8.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.2. Stroke Phase I
8.8.2.1. Stroke Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.3. Stroke Phase II
8.8.3.1. Stroke Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.4. Stroke Phase III
8.8.4.1. Stroke Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.5. Stroke Phase IV
8.8.5.1. Stroke Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.9. Traumatic Brain Injury (TBI)
8.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.9.2. Traumatic Brain Injury (TBI) Phase I
8.9.2.1. Traumatic Brain Injury (TBI) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.9.3. Traumatic Brain Injury (TBI) Phase II
8.9.3.1. Traumatic Brain Injury (TBI) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.9.4. Traumatic Brain Injury (TBI) Phase III
8.9.4.1. Traumatic Brain Injury (TBI) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.9.5. Traumatic Brain Injury (TBI) Phase IV
8.9.5.1. Traumatic Brain Injury (TBI) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.10. Amyotrophic Lateral Sclerosis (ALS)
8.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.10.2. Amyotrophic Lateral Sclerosis (ALS) Phase I
8.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.10.3. Amyotrophic Lateral Sclerosis (ALS) Phase II
8.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.10.4. Amyotrophic Lateral Sclerosis (ALS) Phase III
8.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.10.5. Amyotrophic Lateral Sclerosis (ALS) Phase IV
8.10.5.1. Amyotrophic Lateral Sclerosis (ALS) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.11. Huntington's Disease
8.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.11.2. Huntington's Disease Phase
8.11.2.1. Huntington's Disease Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.11.3. Huntington's Disease Phase II
8.11.3.1. Huntington's Disease Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.11.4. Huntington's Disease Phase III
8.11.4.1. Huntington's Disease Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.11.5. Huntington's Disease Phase IV
8.11.5.1. Huntington's Disease Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.12. Muscle Regeneration
8.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.12.2. Muscle Regeneration Phase I
8.12.2.1. Muscle Regeneration Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.12.3. Muscle Regeneration Phase II
8.12.3.1. Muscle Regeneration Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.12.4. Muscle Regeneration Phase III
8.12.4.1. Muscle Regeneration Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.12.5. Muscle Regeneration Phase IV
8.12.5.1. Muscle Regeneration Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.13. Others
8.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.13.2. Others Phase I
8.13.2.1. Others Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.13.3. Others Phase II
8.13.3.1. Others Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.13.4. Others Phase III
8.13.4.1. Others Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.13.5. Others Phase IV
8.13.5.1. Others Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. U.S. Neurology Clinical Trials Market: Value Chain Estimates & Trend Analysis
9.1. U.S. Neurology Clinical Trials Market, By Value Chain: Segment Dashboard
9.2. U.S. Neurology Clinical Trials Market, By Value Chain: Movement Analysis
9.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Value Chain, 2021 - 2033 (USD Million)
9.4. In-house
9.4.1. In-house Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. CROs
9.5.1. CROs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Investigator Sites/Clinical Sites
9.6.1. Investigator Sites/Clinical Sites Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Market Participant Categorization
10.1.1. Market Leaders
10.1.2. Emerging Players
10.2. Market Assessment Analysis, 2024 (Heat Map Analysis)
10.3. Company Profiles
10.3.1. Syneos Health
10.3.1.1. Company Overview
10.3.1.2. Financial Performance
10.3.1.3. Service Benchmarking
10.3.1.4. Strategic Initiatives
10.3.2. Icon Plc
10.3.2.1. Company Overview
10.3.2.2. Financial Performance
10.3.2.3. Service Benchmarking
10.3.2.4. Strategic Initiatives
10.3.3. Lindus Health
10.3.3.1. Company Overview
10.3.3.2. Financial Performance
10.3.3.3. Service Benchmarking
10.3.3.4. Strategic Initiatives
10.3.4. AbbVie
10.3.4.1. Company Overview
10.3.4.2. Financial Performance
10.3.4.3. Service Benchmarking
10.3.4.4. Strategic Initiatives
10.3.5. GlaxoSmithKline
10.3.5.1. Company Overview
10.3.5.2. Financial Performance
10.3.5.3. Service Benchmarking
10.3.5.4. Strategic Initiatives
10.3.6. Labcorp Drug Development
10.3.6.1. Company Overview
10.3.6.2. Financial Performance
10.3.6.3. Service Benchmarking
10.3.6.4. Strategic Initiatives
10.3.7. Pfizer
10.3.7.1. Company Overview
10.3.7.2. Financial Performance
10.3.7.3. Service Benchmarking
10.3.7.4. Strategic Initiatives
10.3.8. AstraZeneca
10.3.8.1. Company Overview
10.3.8.2. Financial Performance
10.3.8.3. Service Benchmarking
10.3.8.4. Strategic Initiatives
10.3.9. Biogen
10.3.9.1. Company Overview
10.3.9.2. Financial Performance
10.3.9.3. Service Benchmarking
10.3.9.4. Strategic Initiatives
10.3.10. Eli Lilly
10.3.10.1. Company Overview
10.3.10.2. Financial Performance
10.3.10.3. Service Benchmarking
10.3.10.4. Strategic Initiatives
10.3.11. Alzheon
10.3.11.1. Company Overview
10.3.11.2. Financial Performance
10.3.11.3. Service Benchmarking
10.3.11.4. Strategic Initiatives
10.3.12. BDD Pharma
10.3.12.1. Company Overview
10.3.12.2. Financial Performance
10.3.12.3. Service Benchmarking
10.3.12.4. Strategic Initiatives


L